FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer Medical Dialogues Bureau1 March 2020 2:00 PM ISTThe ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
